Fig. 2From: Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disordersGene therapies in SMA. Overview of the currently available therapies for spinal muscular atrophy (SMA): Antisense Oligonucleotide (ASO: Nusinersen), small molecule (Risdiplam), AAV9 gene delivery approach (Onasemnogene abeparvovec)—and corresponding clinical trialsBack to article page